← Eichor
Study identifier: NCT06608134 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis

Condition: Osteoarthritis, Knee  ·  Sponsor: R3 Medical Research

PhaseEARLY_Phase 1
Planned participants120
Who can joinAll sexes, 30 Years to no upper limit
Healthy volunteersNo

About this study

This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (5)

R3 Anti Aging ScottsdaleScottsdale, Arizona, United StatesRecruiting
R3 Anti Aging Beverly HillsBeverly Hills, California, United StatesRecruiting
Optimal Medical GroupFresno, California, United StatesRecruiting
Scheer Medical WellnessNew York, New York, United StatesRecruiting
Dr. Duc (Steve) Le, MDCleveland, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06608134